Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

Lisa M. Blanchette; Joseph L. Kuti; David P. Nicolau; Michael D. Nailor

doi:10.3109/00365548.2014.954262

journal article Sep 29, 2014

Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

Lisa M. Blanchette Joseph L. Kuti

David P. Nicolau Michael D. Nailor

Scandinavian Journal of Infectious Diseases Vol. 46 No. 11 pp. 803-808 · Informa UK Limited

View at Publisher Save 10.3109/00365548.2014.954262

Topics

No keywords indexed for this article. Browse by subject →

References

24

[1]

10.1007/bf02013107

[2]

Jones RN Diagn Microbiol Infect Dis (1998) 10.1016/s0732-8893(98)00029-7

[3]

Negri MC Clin Microbiol Infect (1998) 10.1111/j.1469-0691.1998.tb00041.x

[4]

Chow JW Ann Intern Med (1991) 10.7326/0003-4819-115-8-585

[5]

Choi SH Antimicrob Agents Chemother (2008) 10.1128/aac.01083-07

[6]

10.1001/archinte.162.2.185

[7]

Hilty M Int J Antimicrob Agents (2013) 10.1016/j.ijantimicag.2012.10.022

[8]

Sanders WE Clin Infect Dis (1996) 10.1093/clinids/23.3.454

[9]

The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae

Pranita D. Tamma, Sonya C. T. Girdwood, Ravindra Gopaul et al.

Clinical Infectious Diseases 2013 10.1093/cid/cit395

[10]

Bellido F Antimicrob Agents Chemother (1991) 10.1128/aac.35.1.73

[11]

Yang Y J Antimicrob Chemother (1995) 10.1093/jac/35.1.75

[12]

Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*

Anand Kumar, DANIEL ROBERTS, Kenneth E. Wood et al.

Critical Care Medicine 2006 10.1097/01.ccm.0000217961.75225.e9

[13]

Dellinger RP Crit Care Med (2013) 10.1097/ccm.0b013e31827e83af

[14]

Hombach M J Antimicrob Chemother (2012) 10.1093/jac/dkr524

[15]

Bassetti M J Antimicrob Chemother (2007) 10.1093/jac/dkm180

[16]

Pai H Antimicrob Agents Chemother (2004) 10.1128/aac.48.10.3720-3728.2004

[17]

Trouillet JL Am J Respir Crit Care Med (1998) 10.1164/ajrccm.157.2.9705064

[18]

Paterson DL Clin Infect Dis (2004) 10.1086/382690

[19]

Eagye KJ Infect Control Hosp Epidemiol (2010) 10.1086/652154

[20]

McDougall DA J Antimicrob Chemother (2013) 10.1093/jac/dks385

[21]

Falagas ME Expert Rev Anti Infect Ther (2013) 10.1586/eri.12.149

[22]

Livermore DM J Antimicrob Chemother (2005) 10.1093/jac/dki009

[23]

Bhargava A Infect Control Hosp Epidemiol (2014) 10.1086/675614

[24]

Swaminathan M Infect Control Hosp Epidemiol (2013) 10.1086/671270

Cited By

21

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul, Elena Carrara · 2022

Clinical Microbiology and Infection

Metrics

21

Citations

24

References

Details

Published: Sep 29, 2014
Vol/Issue: 46(11)
Pages: 803-808

Authors

Center for Anti‐Infective Research and Development Hartford Hospital Hartford Connecticut USA

D

David P. Nicolau

Center for Anti-Infective Research and Development, Hartford, Connecticut 06102; Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut 06102

M

Michael D. Nailor

Cite This Article

Lisa M. Blanchette, Joseph L. Kuti, David P. Nicolau, et al. (2014). Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scandinavian Journal of Infectious Diseases, 46(11), 803-808. https://doi.org/10.3109/00365548.2014.954262

Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

You May Also Like